White House spokeswoman Karina Jean-Pierre denied a report in the U.S. media on the 8th that President Joseph Biden did not receive treatment for Parkinson's disease. Biden had the first televised debate of the 2024 presidential election with Republican opponent Donald Trump on June 27, and his poor performance on the spot triggered discussions about his physical condition. The New York Times reported that a doctor specializing in the treatment of Parkinson's disease had "visited" the White House eight times from August last year to March this year. Facing the media's questions about Biden's health, Jean-Pierre asked and answered himself at a regular White House press conference on the 8th: "Has the president received treatment for Parkinson's disease? No. Is he currently receiving treatment for Parkinson's disease? No, he is not. Is he taking medication for Parkinson's disease? No." Jean-Pierre said Biden had seen a neurologist three times, all related to his annual physical examination. She also took out the report issued by the doctor after Biden's most recent physical examination in February this year. The report said, "An extremely detailed neurological examination was once again reassuring" because no symptoms consistent with stroke, multiple sclerosis or Parkinson's disease were found. The doctor who went to the White House mentioned by the New York Times is Kevin Kanal, a neurology and movement disorder expert at the Walter Reed National Military Medical Center in Maryland and an authority on Parkinson's disease. Jean-Pierre suggested that the doctor might have come to treat military personnel on duty at the White House.

In a groundbreaking discovery, researchers from the Xinjiang Institute of Ecology and Geography of the Chinese Academy of Sciences have found a desert moss species, known as Syntrichia caninervis, that has the potential to survive in the extreme conditions on Mars. The Global Times learned from the institute that during the third Xinjiang scientific expedition, the research team focused on studying the desert moss and found that it not only challenges people's understanding of the tolerance of organisms in extreme environments, but also demonstrates the ability to survive and regenerate under simulated Martian conditions. Supported by the Xinjiang scientific expedition project, researchers Li Xiaoshuang, Zhang Daoyuan and Zhang Yuanming from the Xinjiang Institute of Ecology and Geography and Kuang Tingyun, an academician from the Chinese Academy of Sciences, concentrated on studying the "pioneer species" Syntrichia caninervis in an extreme desert environment, according to the institute in an article it sent to the Global Times on Sunday. Through scientific experiments, the researchers systematically proved that the moss can tolerate over 98 percent cell dehydration, survive at temperatures as low as -196 C without dying, withstand over 5000Gy of gamma radiation without perishing, and quickly recover, turn green, and resume growth, showcasing extraordinary resilience. These findings push the boundaries of human knowledge on the tolerance of organisms in extreme environments. Furthermore, the research revealed that under simulated Martian conditions with multiple adversities, Syntrichia caninervis can still survive and regenerate when returned to suitable conditions. This marks the first report of higher plants surviving under simulated Martian conditions. The research team also identified unique characteristics of Syntrichia caninervis. Its overlapping leaves reduce water evaporation, while the white tips of the leaves reflect intense sunlight. Additionally, the innovative "top-down" water absorption mode of the white tips efficiently collects and transports water from the atmosphere. Moreover, the moss can enter a selective metabolic dormancy state in adverse environments and rapidly provide the energy needed for recovery when its surrounding environment improves. Based on the extreme environmental tolerance of Syntrichia caninervis, the research team plans to conduct experiments on spacecraft to monitor the survival response and adaptation capabilities of the species under microgravity and various ionizing radiation adversities. They aim to unravel the physiological and molecular basis of the moss and explore the key life tolerance regulatory mechanisms, laying the foundation for future applications of Syntrichia caninervis in outer space colonization.

The tetraprism lens with 5x optical zoom currently exclusive to the iPhone 15 Pro Max could be headed to both the iPhone 16 Pro and iPhone 16 Pro Max, narrowing the gap between Apple's premium flagships. That's according to a new report from analyst Ming-Chi Kuo, who cites a recent earnings call with Apple lens supplier Largan. In the call, a spokesperson from Largan said "some flagship specifications will be extended to other models" in the second half of 2024, presumably in reference to the upcoming iPhone Pro models. "Apple is Largan’s largest customer, and Largan is also Apple’s largest lens supplier," Kuo said. "Therefore, the quote likely refers to the fact that the new iPhone 16 Pro and Pro Max will have a tetraprism camera in 2H24 (while only the iPhone 15 Pro Max had this camera in 2H23).” The report goes on to say that the tetraprism camera for the iPhone 16 Pro series won't be all that different from the one in the iPhone 15 Pro Max. While the lack of an upgrade is disappointing, it's not necessarily a bad thing as these kinds of lenses are already top-of-the-line. They represent a major increase over prior models’ zoom capabilities, and they're capable of offering more depth while still fitting into super-slim smartphones. That being said, Apple does appear to be revamping the main camera and ultra-wide camera on the iPhone 16 Pro Max. Evidence continues to mount that both iPhone 16 Pro models will share the same 5x optical zoom camera. Earlier this week, DigitTimes in Asia (via 9to5Mac) reported that Apple is set to ramp up orders for tetraprism lenses as it expands their use in its upcoming iPhone series. Industry sources told the outlet that Largan and Genius Electronic Optical were tapped as the primary suppliers. Apple would be wise to streamline its Pro-level iPhones with the same camera setup; then all customers have to consider with their choice of a new iPhone is the size and price. Of course, this should all be taken with a grain of sand for now until we hear more from Apple. It's still a while yet before Apple's usual September time window for iPhone launches. In the meantime, be sure to check out all the rumors so far in our iPhone 16, iPhone 16 Pro and iPhone 16 Pro Max hubs.

The world's first portable electrocardiograph was an 85-pound backpack, and now a 10-gram patch attached to your chest can transmit electrocardiograms uninterrupted for two weeks. The Apple Watch, which is worn by an estimated 100 million people, can send a text message to alert people when their heartbeat is irregular. Wearable sensors on the arms, wrists and fingers can now report arrhythmias, blood sugar levels, blood oxygen and other health indicators. Medical journals have also proposed a more ambitious vision - wearable devices can monitor patients with chronic diseases, eliminating the need for frequent hospital visits. They can spot potential health problems before a stroke or diabetes develops. The forces of health technology and wearables are converging. Tech giants like Apple (AAPL) and Alphabet's (GOOGL) Google are adding health features to their products. Medical technologists like electrocardiogram patch maker iRhythm Technologies or blood sugar monitor makers DexCom (DXCM) and Abbott Laboratories (ABT) are taking their devices beyond the clinic. "In the sensor world, people started on the consumer side and wanted to get into health care," said Kevin Sayer, chief executive of Decon Medical. "In health care, we're trying to be more consumer oriented, and I think all of those things are sort of colliding." Early bets favored the tech giants, with every health-related announcement from Apple, Google or Samsung Electronics hitting medical tech stocks. But changing doctors' practices will also require sustained investment in clinical trials. Big tech companies have cut back on investments in health care. Now it seems that medical technologists will be at the vanguard of the digital health revolution - with smartwatches and smart rings bringing them more customers who need to be diagnosed. Blake Goodner, co-founder of Bridger Management, a hedge fund focused on health care, said: "A group of medtech companies focused on digital health are maturing and reaching a scale where they can not only be profitable but also make investments to compete with larger tech companies." Tech giants aren't getting out of the health business. Apple's smartwatch has an electronic heart rate sensor that generates a single-point electrocardiogram, a wrist temperature sensor, and an accelerometer that can detect violent falls. Hundreds of millions of people are wearing smartwatches with health features from Apple or its rivals Samsung and Garmin.

Apple is giving the Apple Watch a major update for its 10th anniversary. The watch's display will be larger, and the entire device will be thinner and lighter. Both the Apple Watch Series 10 and the new Apple Watch Ultra 3 will be equipped with new chips, which may be paving the way for future Apple AI capabilities. According to sources, the Apple Watch health detection function has encountered some technical obstacles in the upgrade process, the blood pressure measurement function or can only realistically display fluctuations and cannot display values, and the sleep apnea detection and other functions can not appear on the new product. The shell material of Apple Watch SE series products may be replaced by hard plastic from aluminum shell. The plastic-clad Apple Watch may be sold at a lower price to compete with Samsung's cheapest Watch, the Galaxy Watch FE. In addition, Siri's new features may be delayed, and AirPods with cameras may arrive in 2026.